Intermittent chemotherapy in metastatic androgen-independent prostate cancer

T. M. Beer, M. Garzotto, W. D. Henner, K. M. Eilers, E. M. Wersinger

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml-1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

Original languageEnglish (US)
Pages (from-to)968-970
Number of pages3
JournalBritish Journal of Cancer
Issue number6
StatePublished - Sep 15 2003


  • Calcitriol
  • Chemotherapy
  • Docetaxel
  • Prostate cancer
  • Vitamin D

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Intermittent chemotherapy in metastatic androgen-independent prostate cancer'. Together they form a unique fingerprint.

Cite this